Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone reduces disease risk
Bristol-Myers Squibb announced that the ELOQUENT-3 trial, an international Phase 2 study evaluating the addition of Empliciti (elotuzumab) to pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma, achieved its primary endpoint. June 17, 2018